Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (323)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (10)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (655)
  2. Center for Hematologic Malignancies (655)
  3. Department of Medicine (655)
  4. Hematologic Malignancies, Division of (655)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (118)
  3. Jae Park (81)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Blood Advances (27)
  4. Leukemia Research (27)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (25)

More Publications

Publishers
  1. American Society of Hematology (301)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (655)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA
    Meeting Abstract

    Ball, B. J.; Famulare, C.; Stein, E. M.; Tallman, M. S.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; Testi, R.; Al Ali, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of pre-transplant measurable residual disease on relapse incidence and progression-free survival in older AML/MDS patients following allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Perales, M. A.; Papadopoulos, E. B.; Castro-Malaspina, H.; Gyurkocza, B.; Shaffer, B. C.; Tamari, R.; Tallman, M.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Superior survival with post-remission pediatric-inspired chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in adolescents and young adults with ph-negative acute lymphoblastic leukemia in first complete remission: Comparison of CALGB 10403 to patients reported to the CIBMTR
    Meeting Abstract

    Wieduwilt, M. J.; Stock, W.; Advani, A. S.; Luger, S. M.; Larson, R. A.; Tallman, M. S.; Appelbaum, F. R.; Zhang, M. J.; Bo-Subait, K.; Sandmaier, B. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Complex polyclonal resistance mechanisms to ivosidenib monotherapy in IDH1-mutant relapsed or refractory acute myeloid leukemia revealed by single cell sequencing analyses
    Meeting Abstract

    Wang, H.; Choe, S.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Combined treatment with lenalidomide and epoetin alfa leads to durable responses in patients with epo-refractory, lower risk non-deletion 5q [del(5q)] MDS: Final results of the E2905 intergroup phase III study - An ECOG-ACRIN Cancer Research Group study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
    Meeting Abstract

    List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K.; Maciejewski, J. P.; Komrokji, R. S.; Wassenaar, T. R.; Luger, S. M.; Mattison, R. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Paietta, E.; Racevskis, J.; Altman, J. K.; Luger, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Choe, S.; Wang, H.; DiNardo, C. D.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences p53 activity and therapeutic sensitivity via an Evi1-dependent mechanism
    Meeting Abstract

    Cai, S. F.; Chu, S.; Goldberg, A. D.; Parvin, S.; Koche, R.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial
    Meeting Abstract

    Shanafelt, T. D.; Wang, V.; Kay, N. E.; Hanson, C. A.; O'Brien, S. M.; Barrientos, J. C.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2019)

    Fulltext@MSK | Save